Quick-Med Technologies Inc. announced that it has amended its Patent and Technology License Agreement with Derma Sciences Inc. to grant Derma Sciences rights to use NIMBUS(R) technology in an expanded range of wound dressings formats marketed by Derma Sciences under its BIOGUARD(TM) trademark. The amendment also adjusts minimum royalties, provides terms for Derma Sciences entering into a private-label contract, and extends the term of the License for an additional three years subject to Derma Sciences meeting certain milestones and performance requirements. Quick-Med expects NIMBUS to become an important technology in the $14 billion global wound care market as wound care companies and health care professionals look for more effective and efficient ways to prevent infections and avoid cross-contamination. The aging population will continue to drive significant growth in the wound care market while continuing attention on reducing hospital infection rates will accelerate the push for cost-effective antimicrobial dressings. NIMBUS is the first non-leaching antimicrobial available in a wound dressing. It received U.S. Food and Drug Administration clearance in February, 2009 and Derma Sciences introduced its BIOGUARD dressings in June 2009. BIOGUARD dressings are the first wound care products to feature Quick-Med's novel, FDA-cleared NIMBUS technology. The dressings serve as a barrier to infection, kill germs absorbed into the dressing, and do not interfere with tissue healing. The NIMBUS active agent maintains effectiveness even in the presence of large amounts of proteinaceous exudates.

Quick-Med Technologies Inc. announced that it has started to receive royalty payments for its NIMBUS non-leaching antimicrobial technology. The first royalty payment is from Quick-Med licensee Derma Sciences Inc. for initial sales of its BIOGUARD dressings. The royalty payments from late June to 30 September 2009 totalled more than USD 79,000, representing initial BIOGUARD sales of nearly USD 400,000.

Quick-Med Technologies Inc. announced that the Food and Drug Administration has issued guidance to support the classification of the company's NIMBUS(R) barrier gauze wound dressings as Class II medical devices. This novel wound dressing received its initial market clearance on February 25, 2009 via FDA's De Novo review process, a special clearance program for medical devices that are found to be 'not substantially equivalent' to any predicate device. The newly issued guidance pertains to a wound dressing with permanently bound cationic biocide pDADMAC, a key component of the NIMBUS technology and one of the molecular entities covered in nine Quick-Med U.S. patents and patents pending and in 24 foreign counterparts. The guidance document specifies only the cationic biocide polyDADMAC; dressings with other cationic biocides are not within the scope of this guidance.

Quick-Med Technologies Receives Notice of Allowance for Additional NIMBUS(R) Patent

Quick-Med Technologies Notes Recent Changes in Bid/Ask Quote Data for Company Stock

Quick-Med Technologies Receives Notice of Allowance for Additional NIMBUS(R) Patent

QUICK-MED TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E

Quick-Med Technologies Notes Recent Changes in Bid/Ask Quote Data for Company Stock

Derma Sciences Gains Expanded Product Offering and Extended Contract Term for its BIOGUARD(TM) Dressing Line

Derma Sciences Gains Expanded Product Offering and Extended Contract Term for its BIOGUARD(TM) Dressing Line

Medline Industries to Sell BIOGUARD Wound Dressings with NIMBUS® Technology

Quick-Med Technologies Expands NIMBUS® License for Derma Sciences' BIOGUARD Wound Dressings

Derma Sciences Signs Contract With Leading Wound Care Company for Exclusive Distribution of BIOGUARD(TM) Barrier Dressings

Medline Industries to Sell BIOGUARD Wound Dressings with NIMBUS® Technology

Derma Sciences Signs Contract With Leading Wound Care Company for Exclusive Distribution of BIOGUARD(TM) Barrier Dressings

Quick-Med Technologies Expands NIMBUS® License for Derma Sciences' BIOGUARD Wound Dressings

QUICK-MED TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report

QUICK MED TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report

QUICK MED TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E

CEO Interview: Quick-Med Technologies, Inc. - J. Ladd Greeno

FDA Issues Guidance for Derma Sciences' Exclusive Wound Dressing With pDADMAC

FDA Issues Guidance for Quick-Med Technologies' Exclusive Wound Dressing with pDADMAC

Quick-Med Technologies Receives First Royalties for its NIMBUS® Wound Dressings